Menopause cost-effectiveness of therapy
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Rahmah Al-Edresi, M.D.[2]
Overview
Overview
Given the morbidity associated with menopause, and the high cost of HRT and non- hormonal therapy, current pharmacotherapy to treat menopause are cost-effective.
Cost-Effectiveness of Therapy
Cost-Effectiveness of Therapy
- Hormone replacement therapy is cost-effective for the relief of menopausal symptoms either was severe or mild.
- HRT is not cost-effective for asymptomatic women for prevention of medical diseases associated with postmenopause.
- The Cost-effectiveness of hormone replacement therapy ratios between 10,000 – a million $ per QALY (quality-adjusted life expectancy).
- There are several factors that improved cost-effectiveness such as the long duration of therapy, the presence of menopausal symptoms, and minimum side effects of hormonal therapy.
- Non-hormonal therapy such as SNRIs and SSRIs are relatively cost-effectiveness for relief of menopausal symptoms.[1][2][3][4]
References
References
- ↑ Lekander I, Borgström F, Ström O, Zethraeus N, Kanis JA (2009). “Cost-effectiveness of hormone therapy in the United States”. J Womens Health (Larchmt). 18 (10): 1669–77. doi:10.1089/jwh.2008.1246. PMID 19857096.
- ↑ Burger H (2003). “Hormone replacement therapy in the post-Women’s Health Initiative era. Report a a meeting held in Funchal, Madeira, February 24-25, 2003”. Climacteric. 6 Suppl 1: 11–36. PMID 12945798.
- ↑ Cheung AP, Wren BG (1992). “A cost-effectiveness analysis of hormone replacement therapy in the menopause”. Med J Aust. 156 (5): 312–6. PMID 1588862.
- ↑ Williams-Frame A, Carpenter JS (2009). “Costs of hormonal and nonhormonal prescription medications for hot flashes”. Womens Health (Lond). 5 (5): 497–502. doi:10.2217/whe.09.49. PMC 3637932. PMID 19702449.
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH